|
| Press Releases |
|
 |
|
| Wednesday, December 20, 2023 |
|
|
Ocumension Therapeutics: The Approval Received For Marketing OT-703 In Hong Kong, A New Option For Patients With Diabetic Macular Edema |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, is pleased to announce that, OT-703 (ILUVIEN(R), fluocinolone intravitreal implant), an injectable more info >> |
|
| Thursday, August 24, 2023 |
|
|
Ocumension Therapeutics Announces 2023 Interim Results |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, announced its interim results for the six months ended 30 June 2023 ("the Period") today. more info >> |
|
| Thursday, March 30, 2023 |
|
|
Ocumension Therapeutics Announces 2022 Annual Results |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, announced its annual results for the year ended 31 December 2022 today. more info >> |
|
| Monday, March 13, 2023 |
|
|
Ocumension Therapeutics Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a leading China ophthalmic pharmaceutical platform company, is pleased to announce that the Company's ordinary shares, which trade on The Stock Exchange of Hong Kong Limited ("HKEX"), are included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective on March 13, 2023. more info >> |
|
| Tuesday, February 14, 2023 |
|
|
Ocumension Therapeutics Issues Positive Profit Alert for 2022 Annual Results |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, is pleased to announce that it is anticipated that the Company will record a significant increase in its revenue and gross profit for the year ended 31 December 2022 (the "Year 2022"). more info >> |
|
| Friday, February 3, 2023 |
|
|
Ocumension Therapeutics Announces The Completion Of The Phase I Clinical Trial Of Its Class I New Drug For The Treatment Of Dry Eye -- OT-202 |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that the phase I clinical trial of OT-202 (tyrosine kinase inhibitor), a class I new drug developed by the Company for the treatment of dry eye, has been completed successfully. more info >> |
|
| Wednesday, February 1, 2023 |
|
|
Ocumension Therapeutics Announces Its Patient Enrollment Completed In The Phase III Clinical Trail Of OT-101 In China |
| Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that OT-101 (0.01% atropine sulfate eye drop) more info >> |
|
| Monday, January 30, 2023 |
|
|
Ocumension Therapeutics Appoints Mr. Tim RUAN and Mr. WANG Chong as Chief Financial Officer and Head of Investor Relations respectively |
| Ocumension Therapeutics (1477.HK) is pleased to announce that Mr. Tim RUAN and Mr. WANG Chong have been appointed as Chief Financial Officer and Head of Investor Relations respectively of the Group. more info >> |
|
| Saturday, March 20, 2021 |
|
|
Ocumension Therapeutics (1477.HK) Announces 2020 Annual Results |
| The Chinese ophthalmology platform company, Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, the "Group" ), (stock code: 1477.HK), announced its annual results for the year ended 31 December 2020 today. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Batch Bicycles and Hyatt Place Zhuhai jointly organized An Exhalating Cycling Event in Macau 
Apr 23, 2025 19:02 HKT/SGT
|
|
|
EdgePoint Towers advances renewable energy integration in telecommunications with first solar hybrid deployment
Apr 23, 2025 14:00 HKT/SGT
|
|
|
Fujitsu expands strategic collaboration with Supermicro to offer total generative AI platform
Apr 23, 2025 11:55 JST
|
|
|
Furuya Metal and Asahi Kasei Embark on Demonstration Trial Regarding Recycling of Metals for Chlor-alkali Electrolysis Cells and Electrodes
Apr 23, 2025 11:00 JST
|
|
|
Earth Day Special: foundit Report Reveals 27% Surge in Green Jobs as Singapore Accelerates Sustainability Push
Apr 23, 2025 09:00 HKT/SGT
|
|
|
2025 U.S. Open Polo Championship Final Concludes American High-Goal Season, Supported by U.S. Polo Assn.
Apr 22, 2025 19:00 HKT/SGT
|
|
|
A Strategic Event for HR Leaders and Experts to Drive Transformation in the Saudi Workforce
Apr 22, 2025 16:40 HKT/SGT
|
|
|
Under the patronage of Maktoum bin Mohammed DIFC to host 3rd edition of Dubai FinTech Summit on 12-13 May 2025
Apr 22, 2025 16:00 HKT/SGT
|
|
|
New Trading Bot Pivozon Targets Gold Traders Using Hourly Chart Strategies
Apr 22, 2025 15:30 HKT/SGT
|
|
|
A Decade of Olympus India's Commitment to Community Welfare
Apr 22, 2025 13:00 JST
|
|
|
Meerkat ($MERK) introduces utility-focused meme ecosystem with staking, gaming, and AI features
Apr 22, 2025 11:00 HKT/SGT
|
|
|
Fujitsu and RIKEN develop world-leading 256-qubit superconducting quantum computer
Apr 22, 2025 11:37 JST
|
|
|
Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange
Apr 22, 2025 10:16 HKT/SGT
|
|
|
CIRC: Attained a New High in Fiscal Year 2024
Apr 22, 2025 09:52 HKT/SGT
|
|
|
The 3rd International & Indonesia CCS Forum 2025: A Global Collaboration Momentum for CCS Development
Apr 22, 2025 02:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
